Meeting of the Vaccines Federal Implementation Plan, 11724 [2022-04327]
Download as PDF
11724
Federal Register / Vol. 87, No. 41 / Wednesday, March 2, 2022 / Notices
OMB control number 0910–0338; the
collections of information in §§ 201.56
and 201.57 for the content and format
requirements for labeling of human
prescription drug and biological
products have been approved under
OMB control number 0910–0572.
In addition, the following collections
of information in FDA’s guidances have
been approved by OMB (https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents):
• Collections in FDA’s draft guidance
for industry entitled ‘‘Formal Meetings
Between the FDA and Sponsors and
Applicants for PDUFA Products’’ have
been approved under OMB control
number 0910–0429.
• Collections in FDA’s guidance for
industry entitled ‘‘Special Protocol
Assessment’’ have been approved under
OMB control number 0910–0470.
• Collections in FDA’s guidance for
industry entitled ‘‘Establishment and
Operation of Clinical Trial Data
Monitoring Committees’’ have been
approved under OMB control number
0910–0581.
• Collections in FDA’s guidance for
industry entitled ‘‘Oversight of Clinical
Investigations—A Risk-Based Approach
to Monitoring’’ have been approved
under OMB control number 0910–0733.
• Collections in FDA’s guidance for
industry entitled ‘‘Expedited Programs
for Serious Conditions—Drugs and
Biologics’’ have been approved under
OMB control number 0910–0765.
• Collections in FDA’s guidance for
industry entitled ‘‘E6(R2) Good Clinical
Practice: Integrated Addendum to ICH
E6(R1)’’ have been approved under
OMB control number 0910–0843.
III. Electronic Access
lotter on DSK11XQN23PROD with NOTICES1
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: February 24, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–04398 Filed 3–1–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Vaccines Federal
Implementation Plan
National Institutes of Health
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health, Office of Infectious Disease and
HIV/AIDS Policy.
AGENCY:
ACTION:
Notice.
17:34 Mar 01, 2022
The Department of Health and
Human Services’ Office of Infectious
Disease and HIV/AIDS Policy in the
Office of the Assistant Secretary for
Health announces that the draft
Vaccines Federal Implementation Plan
2021–2025 is available for public
comment. The Vaccines Federal
Implementation Plan is a companion
document to the Vaccines National
Strategic Plan 2021–2025 (VNSP),
which was published in January 2021.
The Vaccines Federal Implementation
Plan is a compilation of federal agency
immunization activities that collectively
advance the goals of the VNSP. Its target
audience is other federal agencies and
external partners who work in the area
of vaccination. The public will be
interested in how the implementation
plan documents federal agency efforts. It
does not outline mandates or other
COVID–19 response measures.
SUMMARY:
The public comment period for
the Vaccines Federal Implementation
Plan starts on February 28, 2022 at 9
a.m. ET and ends on March 29, 2022 at
5 p.m. ET. All comments must be
received by 5 p.m. ET on March 29,
2022 to be considered.
DATES:
All comments must be
submitted electronically to nvp.rfi@
hhs.gov.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
David Kim, MD, MA, Director, Division
of Vaccines, Office of Infectious Disease
and HIV/AIDS Policy, Office of the
Assistant Secretary for Health, U.S.
Department of Health and Human
Services, Room L616, Switzer Building,
330 C St. SW, Washington, DC 20024.
Phone: 202–795–7697; Email: nvp.rfi@
hhs.gov.
Dated: February 17, 2022.
David Kim,
Designated Federal Officer, Vaccines Federal
Implementation Plan, Office of the Assistant
Secretary for Health.
[FR Doc. 2022–04327 Filed 3–1–22; 8:45 am]
Jkt 256001
PO 00000
Frm 00039
Fmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This notice announces the
next meeting of the National Toxicology
Program (NTP) Board of Scientific
Counselors (BSC). The BSC, a federally
chartered, external advisory group
composed of scientists from the public
and private sectors, will review and
provide advice on programmatic
activities. This meeting is a virtual
meeting and is open to the public.
Written comments will be accepted and
registration is required to present oral
comments.
SUMMARY:
BILLING CODE 4150–44–P
VerDate Sep<11>2014
National Toxicology Program Board of
Scientific Counselors; Announcement
of Meeting; Request for Comments
Sfmt 4703
DATES:
Meeting: Scheduled for April 19,
2022, 12:30 p.m.–2:00 p.m. Eastern
Standard Time (EST). Ending times are
approximate; meeting may end earlier or
run later.
Written Public Comment
Submissions: Deadline is April 12, 2022.
Registration for Oral Comments:
Deadline is April 12, 2022.
ADDRESSES:
Meeting Web Page: The preliminary
agenda, registration, and other meeting
materials will be available at https://
ntp.niehs.nih.gov/go/165 by March 14,
2022.
Virtual Meeting: The URL for viewing
the virtual meeting will be provided on
the meeting web page the day before the
meeting.
FOR FURTHER INFORMATION CONTACT: Dr.
Mary Wolfe, Designated Federal Official
for the BSC, Office of Policy, Review,
and Outreach, Division of NTP, NIEHS,
P.O. Box 12233, K2–03, Research
Triangle Park, NC 27709. Phone: 984–
287–3209, Fax: 301–451–5759, Email:
wolfe@niehs.nih.gov. Hand Deliver/
Courier address: 530 Davis Drive, Room
K2130, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION: The BSC
will provide input to the NTP on
programmatic activities and issues. The
preliminary agenda topics include
presentations on a contract concept:
Bioinformatics Support for the NIEHS.
The preliminary agenda, roster of BSC
members, background materials, public
comments, and any additional
information, when available, will be
posted on the BSC meeting web page
(https://ntp.niehs.nih.gov/go/165) or
E:\FR\FM\02MRN1.SGM
02MRN1
Agencies
[Federal Register Volume 87, Number 41 (Wednesday, March 2, 2022)]
[Notices]
[Page 11724]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04327]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Vaccines Federal Implementation Plan
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of the Assistant Secretary for Health, Office of
Infectious Disease and HIV/AIDS Policy.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services' Office of
Infectious Disease and HIV/AIDS Policy in the Office of the Assistant
Secretary for Health announces that the draft Vaccines Federal
Implementation Plan 2021-2025 is available for public comment. The
Vaccines Federal Implementation Plan is a companion document to the
Vaccines National Strategic Plan 2021-2025 (VNSP), which was published
in January 2021. The Vaccines Federal Implementation Plan is a
compilation of federal agency immunization activities that collectively
advance the goals of the VNSP. Its target audience is other federal
agencies and external partners who work in the area of vaccination. The
public will be interested in how the implementation plan documents
federal agency efforts. It does not outline mandates or other COVID-19
response measures.
DATES: The public comment period for the Vaccines Federal
Implementation Plan starts on February 28, 2022 at 9 a.m. ET and ends
on March 29, 2022 at 5 p.m. ET. All comments must be received by 5 p.m.
ET on March 29, 2022 to be considered.
ADDRESSES: All comments must be submitted electronically to
[email protected].
FOR FURTHER INFORMATION CONTACT: David Kim, MD, MA, Director, Division
of Vaccines, Office of Infectious Disease and HIV/AIDS Policy, Office
of the Assistant Secretary for Health, U.S. Department of Health and
Human Services, Room L616, Switzer Building, 330 C St. SW, Washington,
DC 20024. Phone: 202-795-7697; Email: [email protected].
Dated: February 17, 2022.
David Kim,
Designated Federal Officer, Vaccines Federal Implementation Plan,
Office of the Assistant Secretary for Health.
[FR Doc. 2022-04327 Filed 3-1-22; 8:45 am]
BILLING CODE 4150-44-P